ASPN sirna

ASPN siRNA (Human)

Cat. Num. AAA8231677

• Gene Names: ASPN; OS3; PLAP1; PLAP-1; SLRR1C
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: ASPN; ASPN siRNA (Human); PLAP1; SLRR1C; Asporin; Periodontal ligament-associated protein 1; PLAP-1; ASPN sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: ASPN siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 242

• Applicable Applications for ASPN sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ASPN gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Ships on blue ice.; Store at -20 degree C for one year.

Related Product Information for ASPN sirna

siRNA to inhibit ASPN expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 301069324
• NCBI GeneID: 54829
• NCBI Accession #: NP_001180264.1
• NCBI GenBank Nucleotide #: NM_001193335.1
• UniProt Accession #: Q9BXN1; Q5TBF3; Q96K79; Q96LD0; Q9NXP3
• NCBI Official Full Name: asporin isoform 2 preproprotein
• NCBI Official Synonym Full Names: asporin
• NCBI Official Symbol: ASPN
• NCBI Official Synonym Symbols: OS3; PLAP1; PLAP-1; SLRR1C
• NCBI Protein Information: asporin
• UniProt Protein Name: Asporin
• Protein Family: Asporin
• UniProt Gene Name: ASPN
• UniProt Synonym Gene Names: PLAP1; SLRR1C; PLAP-1
• UniProt Entry Name: ASPN_HUMAN

NCBI Description

This gene encodes a cartilage extracellular protein that is member of the small leucine-rich proteoglycan family. The encoded protein may regulate chondrogenesis by inhibiting transforming growth factor-beta 1-induced gene expression in cartilage. This protein also binds collagen and calcium and may induce collagen mineralization. Polymorphisms in the aspartic acid repeat region of this gene are associated with a susceptibility to osteoarthritis, and also with intervertebral disc disease. Alternative splicing of this gene results in multiple transcript variants.[provided by RefSeq, Jul 2014]

Uniprot Description

ASPN: Negatively regulates periodontal ligament (PDL) differentiation and mineralization to ensure that the PDL is not ossified and to maintain homeostasis of the tooth-supporting system. Inhibits BMP2-induced cytodifferentiation of PDL cells by preventing its binding to BMPR1B/BMP type-1B receptor, resulting in inhibition of BMP-dependent activation of SMAD proteins. Critical regulator of TGF-beta in articular cartilage and plays an essential role in cartilage homeostasis and osteoarthritis (OA) pathogenesis. Negatively regulates chondrogenesis in the articular cartilage by blocking the TGF- beta/receptor interaction on the cell surface and inhibiting the canonical TGF-beta/Smad signal. Binds calcium and plays a role in osteoblast-driven collagen biomineralization activity. Genetic variations in ASPN are associated with susceptibility to osteoarthritis type 3 (OS3); also known as osteoarthritis of knee/hip. Osteoarthritis is a degenerative disease of the joints characterized by degradation of the hyaline articular cartilage and remodeling of the subchondral bone with sclerosis. Clinical symptoms include pain and joint stiffness often leading to significant disability and joint replacement. Susceptibility to osteoarthritis is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is overrepresented relative to the common allele having 13 aspartic acid repeats (D13). The frequency of the D14 allele increases with disease severity. The D14 allele is also overrepresented in individuals with hip osteoarthritis. Defects in ASPN are a cause of susceptibility to intervertebral disk disease (IDD). A common musculo- skeletal disorder caused by degeneration of intervertebral disks of the lumbar spine. It results in low-back pain and unilateral leg pain. Susceptibility to intervertebral disk disease, particularly lumbar disk degeneration, is conferred by a triplet repeat expansion polymorphism. ASPN allele having 14 aspartic acid repeats in the N-terminal region of the protein (D14), is associated with the disorder in some populations (PubMed:18304494). Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class I subfamily.

Protein type: Secreted, signal peptide; Extracellular matrix; Secreted

Chromosomal Location of Human Ortholog: 9q22

Cellular Component: extracellular matrix; proteinaceous extracellular matrix

Molecular Function: collagen binding; calcium ion binding

Biological Process: negative regulation of transforming growth factor beta receptor signaling pathway; bone mineralization

Disease: Intervertebral Disc Disease; Osteoarthritis Susceptibility 3